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Hypoxia, defined as a decrease of tissue oxygen level, is a characteristic feature 
of locally advanced solid tumors, resulting from an imbalance between the intake and 
consumption of oxygen caused by abnormal vessels in the tumor and the rapid 
proliferation of cancer cells. Hypoxia represents a key microenvironmental stressor 
governing multiple phenomena associated with tumor progression such as 
proliferation, angiogenesis and metastasis. Hypoxia promotes not only the 
invasiveness of tumor cells, but also chemoresistance in cancer. Tumor associated 
macrophages (TAMs) residing at the site of hypoxic region of tumors have been 
known to cooperate with tumor cells, and promote proliferation and chemoresistance. 
Therefore, there is an urgent need for new strategies to alleviate tumor hypoxia and 
enhance chemotherapy response in solid tumors. Herein, we have taken advantage of 
high accumulation of TAMs in hypoxic regions of tumor and high reactivity of 
manganese dioxide nanoparticles (MnO2 NPs) toward hydrogen peroxide (H2O2) for 
the simultaneous production of O2 and regulation of pH to effectively alleviate tumor 
hypoxia by targeted delivery of MnO2 NPs to the hypoxic area. Furthermore, we also 
utilized the ability of hyaluronic acid (HA) modification in reprogramming 
anti-inflammatory, pro-tumoral M2 TAMs to pro-inflammatory, antitumor M1 
macrophages to further enhance the ability of MnO2 NPs to lessen tumor hypoxia and 
modulate chemoresistance. The HA-coated, mannan-conjugated MnO2 particle 
(Man-HA-MnO2) treatment significantly increased tumor oxygenation and 
down-regulated hypoxia-inducible factor-1 α (HIF-1α) and vascular endothelial 
growth factor (VEGF) in the tumor. Combination treatment of the tumors with 
Man-HA-MnO2 NPs and doxorubicin significantly increased apparent diffusion 
coefficient (ADC) values of breast tumor, inhibited tumor growth and tumor cell 
proliferation as compared with chemotherapy alone. In addition, the reaction of 
Man-HA-MnO2 NPs toward endogenous H2O2 highly enhanced T1- and T2- MRI 
performance for tumor imaging and detection. 
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为 2% - 9%（平均为 400 mm Hg），氧分压 ≤ 2%定义为乏氧状态[5]。组织轻度































图 1.1 肿瘤微环境中肿瘤细胞的侵袭过程示意图[1] 
肿瘤在乏氧状态下，肿瘤细胞代谢过程中三羧酸循环发生障碍，转而多进行
无氧糖酵解，释放大量乳酸。同时，乏氧区域肿瘤组织周围脉管系统不完备，代



































































































氧诱导转录因子 HIF-1、HIF-2 表达上调，诱导多种血管生成因子如 VEGF 等大
量分泌，进而促进肿瘤血管新生[48,49]。淋巴管生成状态可作为临床不良预后的初





通过抑制 NK 细胞的细胞溶解活性、降低 DC 的迁移及抗原呈递、促进 CD4+ T
细胞分化为 Th1 细胞，加深免疫抑制作用[51,55]。IL-10 是一种有助于肿瘤免疫逃
逸的抗炎、免疫抑制细胞因子，能够降低抗原呈递。IL-10 可抑制 IFN-γ 表达，
进而刺激幼稚 T 细胞分化，促进肿瘤免疫逃逸过程[53,54]。精氨酸酶-1 使 L-精氨






















中高分子量的 HA 分解为低分子量的 HA 片段，可作为免疫系统的报警信号，可
激活先天免疫应答过程。大量文献指出，低分子量 HA 为单核细胞或巨噬细胞免
疫系统的免疫应答信号源，可通过介导 TLR2-MyD88-IRAK1-TRAF6-PKCζ 
-NK-κB 或 TLR4-TRIF-TBK1-IRF3 免疫依赖途径，激活先天免疫应答，引起巨
噬细胞表型变化[57,58,59,60]。 
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